PLoS ONEMolecular BiologyPeer-reviewed journal article
Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease
Kinya OkamotoiD, Masahiko KodaiD, Toshiaki Okamoto, Takumi OnoyamaiD, Kenichi Miyoshi, Manabu Kishina, Tomomitsu MatonoiD, Jun Kato, Shiho Tokunaga, Takaaki SugiharaiD, Akira HiramatsuiD, Hideyuki HyogoiD, Hiroshi TobitaiD, Shuichi SatoiD, Miwa KawanakaiD, Yuichi Hara, Keisuke HinoiD, Kazuaki ChayamaiD, Yoshikazu Murawaki, Hajime IsomotoiD
Abstract
IntroductionNon-alcoholic fatty liver disease (NAFLD) has a wide spectrum, eventually leading to cirrhosis and hepatic carcinogenesis. We previously reported that a series of microRNAs (miRNAs) mapped in the 14q32.2 maternally imprinted gene region (Dlk1-Dio3 mat) are related to NAFLD development and progression in a mouse model. We examined the suitability of miR-379, a circulating Dlk1-Dio3 mat miRNA, as a human NAFLD biomarker.\n\nMethodsEighty NAFLD patients were recruited for this study. miR-379 was selected from the putative Dlk1-Dio3 mat miRNA cluster because it exhibited the greatest expression difference between NAFLD and non-alcoholic steatohepatitis in our preliminary study. Real-time PCR was used to examine the expression levels of miR-379 and miR-16 as an internal control.\n\nResultsCompared to normal controls, serum miR-379 expression was significantly up-regulated in NAFLD patients. Receiver operating characteristic curve analysis suggested that miR-379 is a suitable marker for discriminating NAFLD patients from controls, with an area under the curve value of 0.72. Serum miR-379 exhibited positive correlations with alkaline phosphatase, total cholesterol, and low-density-lipoprotein cholesterol levels in patients with early stage NAFLD (Brunt fibrosis stage 0 to 1). The correlation between serum miR-379 and cholesterol levels was lost in early stage NAFLD patients treated with statins. Software-based predictions indicated that various energy metabolism-related genes, including insulin-like growth factor-1 (IGF-1) and IGF-1 receptor, are potential targets of miR-379.\n\nConclusionsSerum miR-379 exhibits high potential as a biomarker for NAFLD. miR-379 appears to increase cholesterol lipotoxicity, leading to the development and progression of NAFLD, via interference with the expression of target genes, including those related to the IGF-1 signaling pathway. Our results could facilitate future research into the pathogenesis, diagnosis, and treatment of NAFLD.
- Citations
- 27
- FWCI
- 3.04
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hepatocyte-specific miR-33 deletion attenuates NAFLD-NASH-HCC progression
P. FERNANDEZ TUSSY, J. Sun, … C. Fernandez-Hernando·bioRxiv·Jan 18, 2023
- Elucidation of novel miRNA candidates and their role in unraveling the pathology of Non-Alcoholic Fatty Liver Disease
Bincy Biju, Saheb Singh Chhabra, Chiradeep Sarkar·bioRxiv·Jan 31, 2020
- Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA
Yo Han Lee, Hyun‐Jun Jang, … Jang Hyun Choi·eLifePeer-reviewed·Dec 29, 2021
- Hepatic MCPIP1 protein levels are reduced in NAFLD patients and are predominantly expressed in cholangiocytes and liver endothelium
Natalia Pydyn, Justyna Kadłuczka, … Jerzy Kotlinowski·Hepatology CommunicationsPeer-reviewed·Feb 20, 2023
- Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD
Marcus J. Lyall, Jessy Cartier, … Amanda Jane Drake·Wellcome Open ResearchPeer-reviewed·Aug 22, 2017
- Pre-diabetes linked microRNA miR-193b-3p targets PPARGC1A and increases lipid accumulation in hepatocytes: potential biomarker of fatty liver disease
I. G. Mollet, M. P. Macedo·bioRxiv·Jan 22, 2021